2^nd Annual Congress on Bacterial, Viral and Infectious Diseases June 17-18, 2019 Dubai, UAE

Robert O Young is currently working as a Professor at Capital University in Washington, DC. He has completed his MS in Nutrition from the American College in Birmingham, Alabama and DSc with emphasis in Chemistry and Biology and also s PhD from Clayton College of Natural Health.

Cystic Fibrosis (CF) and Pulmonary Adenocarcinoma (PAC) have similar symptomologies and are chronic, progressive and frequently fatal acidic conditions of the respiratory system (lungs), lymphatic system (lymph nodes), intestines, pancreas, urinary tract system, reproductive organs and the skin as the alkaloid glands (the salivary glands, stomach and small and large intestines) produce and secrete alkaline compounds, such as sodium bicarbonate to buffer and preserve the alkaline design of the body and the specific organs and glands affected. These metabolic and dietary acidic conditions resulting in the build-up of mucous can affect any organ or organ system but primarily affects the respiratory, lymphatic system, digestive and reproductive tracts in children and young adults with CF and the lungs and surrounding lymph nodes in PAC. I have suggested from my own clinical research that both of these conditions are the result of Latent Tissue Acidosis (LTA) in the interstitial fluids of the Interstitium or the fluids that surround every cell, created from metabolism, diet, thoughts and environment and may be successfully treated and reversed with an Alkaline

Lifestyle and Diet (ALD).

Galina Migalko brings more than 30 years of excellence in non-invasive diagnostic medical imaging. Her pioneering research in non-invasive whole-body medical diagnosis has set her apart as the World’s leader in holistic medical diagnostics. This unique form of testing the complete anatomy, physiology and functionality of the body has saved her patients time, money, unnecessary medical treatments and necessary medical treatments that were unknown as she identifies and then educates her patients in the root causes of their health issues.

Ayman Noreddin has received his PhD in Pharmaceutical Sciences from the University of the Pacific, California. His research interest includes Pharmacokinetics/Pharmacodynamics’ Modeling of Anti-infective and Anti-cancer Therapy, Clinical Simulation and Monte Carlo Analysis and Bacterial Resistance in Biofilm studies. He served as a Scientific Reviewer for the NIH as well as other national and international research institutions.

Streptococcal pneumonia is a major cause of morbidity and mortality worldwide. Fluoroquinolones are one of the mainstay drugs for treatment of these infections. However emerging resistance poses a threat to the class’s future utility. Using Monte Carlo simulation, we evaluated the probable efficacy of Ciprofloxacin, Levofloxacin, Gemifloxacin, Garenoxacin, and Moxifloxacin in eradicating infections and preventing continued growth of resistance. Using patient data from strep pneumonia patients in hospitals and MIC data from the cross study; drug regimens were compared to see the likelihood of attaining fAUC0-24/ MICall ratios depicting goal clinical outcomes. Very few regimens are able to prevent further growth of resistant organisms when ParC mutations have occurred. Only garenoxacin and Moxifloxacin were able to eradicate extremely resistant isolates in serumand ELF respectively.

Ayman Noreddin has received his PhD in Pharmaceutical Sciences from the University of the Pacific, California. His research interest

includes Pharmacokinetics/Pharmacodynamics’ Modeling of Anti-infective and Anti-cancer Therapy, Clinical Simulation and Monte Carlo Analysis and Bacterial Resistance in Biofilm studies. He served as a Scientific Reviewer for the NIH as well as other national and international research institutions.

Streptococcal pneumonia is a major cause of morbidity and mortality worldwide. Fluoroquinolones are one of the mainstay drugs for treatment of these infections. However emerging resistance poses a threat to the class’s future utility. Using Monte Carlo simulation, we evaluated the probable efficacy of Ciprofloxacin, Levofloxacin, Gemifloxacin, Garenoxacin, and Moxifloxacin in eradicating infections and preventing continued growth of resistance. Using patient data from strep pneumonia patients in hospitals and MIC data from the cross study; drug regimens were compared to see the likelihood of attaining fAUC0-24/ MICall ratios depicting goal clinical outcomes. Very few regimens are able to prevent further growth of resistant organisms when ParC mutations have occurred. Only garenoxacin and Moxifloxacin were able to eradicate extremely resistant isolates in serumand ELF respectively.